You can seek FDA approval to launch a generic drug before the expiration of ABILIFY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ABILIFY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ABILIFY:-

You can seek FDA approval to launch a generic drug before the expiration of ABILIFY MAINTENA KIT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ABILIFY MAINTENA KIT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ABILIFY MAINTENA KIT:-

You can seek FDA approval to launch a generic drug before the expiration of BANZEL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BANZEL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BANZEL:-

You can seek FDA approval to launch a generic drug before the expiration of BEYAZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BEYAZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BEYAZ:-

You can seek FDA approval to launch a generic drug before the expiration of CERDELGA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CERDELGA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CERDELGA:-

You can seek FDA approval to launch a generic drug before the expiration of CHANTIX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CHANTIX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CHANTIX:-

You can seek FDA approval to launch a generic drug before the expiration of COMBIGAN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COMBIGAN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COMBIGAN:-

You can seek FDA approval to launch a generic drug before the expiration of EPIDIOLEX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EPIDIOLEX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EPIDIOLEX:-

You can seek FDA approval to launch a generic drug before the expiration of FOLOTYN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the FOLOTYN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on FOLOTYN:-

You can seek FDA approval to launch a generic drug before the expiration of FUSILEV's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the FUSILEV's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on FUSILEV:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of HETLIOZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the HETLIOZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on HETLIOZ:-

You can seek FDA approval to launch a generic drug before the expiration of HORIZANT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the HORIZANT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on HORIZANT:-

You can seek FDA approval to launch a generic drug before the expiration of JANUMET's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JANUMET's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JANUMET:-

You can seek FDA approval to launch a generic drug before the expiration of JANUMET XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JANUMET XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JANUMET XR:-

You can seek FDA approval to launch a generic drug before the expiration of JANUVIA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JANUVIA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JANUVIA:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of LEXAPRO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LEXAPRO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LEXAPRO:-

You can seek FDA approval to launch a generic drug before the expiration of LEXISCAN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LEXISCAN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LEXISCAN:-

You can seek FDA approval to launch a generic drug before the expiration of LYNPARZA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LYNPARZA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LYNPARZA:-

You can seek FDA approval to launch a generic drug before the expiration of MOVANTIK's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MOVANTIK's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MOVANTIK:-

You can seek FDA approval to launch a generic drug before the expiration of MYRBETRIQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MYRBETRIQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MYRBETRIQ:-

You can seek FDA approval to launch a generic drug before the expiration of NUCYNTA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NUCYNTA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NUCYNTA:-

You can seek FDA approval to launch a generic drug before the expiration of NUCYNTA ER's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NUCYNTA ER's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NUCYNTA ER:-

You can seek FDA approval to launch a generic drug before the expiration of OCALIVA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the OCALIVA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on OCALIVA:-

You can seek FDA approval to launch a generic drug before the expiration of PRISTIQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PRISTIQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PRISTIQ:-

You can seek FDA approval to launch a generic drug before the expiration of PROMACTA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PROMACTA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PROMACTA:-

You can seek FDA approval to launch a generic drug before the expiration of PROMACTA KIT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PROMACTA KIT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PROMACTA KIT:-

You can seek FDA approval to launch a generic drug before the expiration of SAXENDA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SAXENDA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SAXENDA:-

You can seek FDA approval to launch a generic drug before the expiration of STIVARGA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the STIVARGA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on STIVARGA:-

You can seek FDA approval to launch a generic drug before the expiration of TEFLARO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TEFLARO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TEFLARO:-

You can seek FDA approval to launch a generic drug before the expiration of TOVIAZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TOVIAZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TOVIAZ:-

You can seek FDA approval to launch a generic drug before the expiration of TRULANCE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TRULANCE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TRULANCE:-

You can seek FDA approval to launch a generic drug before the expiration of VELCADE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VELCADE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VELCADE:-

You can seek FDA approval to launch a generic drug before the expiration of VICTOZA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VICTOZA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VICTOZA:-

You can seek FDA approval to launch a generic drug before the expiration of VIIBRYD's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VIIBRYD's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VIIBRYD:-

You can seek FDA approval to launch a generic drug before the expiration of VIMPAT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VIMPAT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VIMPAT:-

You can seek FDA approval to launch a generic drug before the expiration of ZIOPTAN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ZIOPTAN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ZIOPTAN:-